Charlottesville, VA – According to filings with the U.S. Securities and Exchange Commission, Adial Pharmaceuticals is raising $5,217,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, William Stilley played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is currently in Phase 3 development as a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency and quantity of drinking and heavy drinking with no overt safety concerns.

To learn more about Adial Pharmaceuticals, visit http://www.adialpharma.com/

Contact:
William Stilley, Chief Executive Officer
434-422-9800
wstilley@adialpharma.com
https://www.linkedin.com/in/williamstilley/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved